BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 122 filers reported holding BRIDGEBIO PHARMA INC in Q2 2020. The put-call ratio across all filers is 0.03 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,501,922 | +56.5% | 284,487 | +2.1% | 0.02% | +57.1% |
Q2 2023 | $4,792,849 | -22.4% | 278,654 | -25.2% | 0.01% | -30.0% |
Q1 2023 | $6,177,509 | +120.4% | 372,588 | +1.3% | 0.02% | +122.2% |
Q4 2022 | $2,802,567 | -26.2% | 367,791 | -1.2% | 0.01% | -35.7% |
Q3 2022 | $3,799,000 | +25.3% | 372,432 | +8.6% | 0.01% | +27.3% |
Q2 2022 | $3,033,000 | -12.8% | 343,069 | +0.1% | 0.01% | +10.0% |
Q1 2022 | $3,480,000 | +65.2% | 342,857 | +171.5% | 0.01% | +100.0% |
Q4 2021 | $2,106,000 | -31.4% | 126,270 | +92.8% | 0.01% | -28.6% |
Q3 2021 | $3,070,000 | -22.6% | 65,504 | +0.7% | 0.01% | -30.0% |
Q2 2021 | $3,964,000 | -39.0% | 65,022 | -38.3% | 0.01% | -44.4% |
Q1 2021 | $6,494,000 | -35.6% | 105,428 | -25.7% | 0.02% | -33.3% |
Q4 2020 | $10,087,000 | +154.1% | 141,849 | +34.1% | 0.03% | +92.9% |
Q3 2020 | $3,969,000 | +22.6% | 105,796 | +6.6% | 0.01% | +16.7% |
Q2 2020 | $3,237,000 | +68.6% | 99,273 | +49.9% | 0.01% | +9.1% |
Q1 2020 | $1,920,000 | – | 66,223 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |